INInMode Ltd. INMD NASDAQ · Healthcare · Israel
$13.27 +0.61% +$0.08
- Market cap
- $759.0M
- Enterprise value
- $367.3M
- P/E
- 9.8x
- Forward P/E
- 9.0x
- PEG
- -
- P/S
- 2.0x
- P/FCF
- 8.7x
- EV/EBITDA
- 4.4x
- ROIC
- 9.2%
- Gross margin
- 76.5%
- Net margin
- 20.7%
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -4.7x
- Beta
- 1.96
- Free float
- 83.6%
About the company
InMode Ltd. (INMD) is a global company specializing in the development and manufacturing of medical devices for aesthetic medicine and surgery. With activities in healthcare technology, InMode Ltd. is a key player in the world of innovative treatment technologies for beauty and aesthetics. Their products include various devices for non-invasive aesthetic procedures, such as fat reduction, skin tightening, and other rejuvenation methods. The company focuses on providing modern and safe solutions for aesthetic treatments that minimize invasiveness and shorten patient recovery times. InMode Ltd. is characterized by technological innovation and the development of advanced medical devices. InMode Ltd. (INMD) shares could be suitable for investors looking for an investment opportunity in the healthcare technology sector with a company that specializes in innovative aesthetic and medical procedures for beauty and enhancement.
Sector
Healthcare
Industry
Medical - Devices
CEO
Moshe Mizrahy
Employees
660
Headquarters
Yokne'am
Valuation
Is today's price reasonable?
- What speaks for it: The share price is below the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What to watch: Revenue fell by 6.6% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: Out of every 100 USD of revenue, 21 USD is left as net profit.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $397.1M against $3.58M.
Capital and dividends
What does the company do with the money it earns?
- What speaks for it: It bought back its own shares for $127.4M in the last fiscal year, 17% of its market value.
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
- What to watch: The price moves much more than the market (beta 1.96).
Statements
Every number